An urgent recall has been issued for a common inhaler used by people with severe asthma.
The UK medicines regulator, the MHRA, have said that the Flutiform 250 micrograms inhaler is to be returned to pharmacies.
A mistake on the labelling means that patients could be informed of the wrong dose of the drug.
Patients have been advised to continue to take the medicine as advised by their doctor and not to return or stop taking the product.
In a statement on the MHRA website they said: ‘This is a wholesale and pharmacy level recall that will be actioned by a healthcare professional. There is no quality issue with the product and patients can continue to take their medicine as prescribed.’
The watchdog was notified by the manufacturer CD pharma limited of the issue.
They said: ‘an error on the outer carton of the product for the batches listed in this notification. While the total active content statement is correct, the delivered dose content statement is incorrect. The other details on the carton are correct.’
The mistake means that patients may have thought that they were only receiving half the necessary dose of the medication.
The respiratory condition asthma affects around 7.2million people in the UK, and asthma attacks kill, on average, three people in Britain every day.
It affects the airways, or breathing tubes, that carry air in and out of the lungs, causing them to become inflamed.
This makes the airways narrower so less air gets into and out of the lungs.
Symptoms include wheezing, breathlessness, a cough or a tight chest — and are often triggered by factors in the environment like pollution, stress or a cold.
Inhalers work to control the disease by reducing the number of blood cells that contribute to the lung inflammation.
This article was originally published by a www.dailymail.co.uk . Read the Original article here. .